Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT05859620
Active, not recruiting Observational

Implementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery

NCT05859620 · tracked via the Priya Life Science Switzerland tracker
Phase
Observational
Started
2021-07-01
Last updated
2026-05-05

Condition(s) studied

Myocardial InjuryMyocardial InfarctionPerioperative Complication

Investigational drug(s) / intervention(s)

Patient assessment and follow-up

Patient assessment and follow-up: There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.

Study summary

The investigators aim to show the feasibility and medicoeconomic impact of implementing a clinical screening and response system for the early detection of perioperative cardiac complications in high-risk patients.

Specifically, the investigators aim to: 1) evaluate the feasibility of implementation of a PMI-screening; 2) evaluate the medicoeconomic impact of implementing a PMI-screening; 3) identify barriers to implementation; 4) generate data for a future randomized controlled trial on outcomes by exploring opportunities to improve care following PMI, the occurrence and timing of major adverse cardiac events (MACE), and the treatment effect associated with PMI-screening.

Eligibility

Sex
ALL
Min age
40 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Consecutive patients fulfilling the institutional criteria for inclusion into the routine PMI-screening * aged 40-85 years * at increased cardiovascular risk * undergoing inpatient, noncardiac, elective or emergent surgery * postoperative stay of ≥2 nights at the participating institution * orthopaedic, traumatology, vascular, spinal, thoracic, neurosurgical, and visceral surgery. Exclusion Criteria: * patients with cardiac surgery or interventions in the last 14 days * chronic renal failure under dialysis, renal transplant surgery * moderate-to-severe dementia * previous inclusion within 5 days * documented refusal to use of their data for research purposes or refusal of further use during follow-up * Patients declining consent for follow-up will be excluded from follow-up analyses.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
University Hospital Innsbruck Innsbruck Tyrol
University Hospital Geneva Geneva Canton of Geneva
Cantonal Hospital Lucerne Lucerne Canton of Lucerne
Canton Hospital Olten Olten Canton of Solothurn
Bürgerspital Solothurn Solothurn Switzerland

More University Hospital, Basel, Switzerland trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05859620 on ClinicalTrials.gov ↗ ← All trials in Switzerland